Strengths

A very high current and quick ratio of 8.6 indicates strong near-term liquidity versus peers, reducing refinancing pressure and supporting operating flexibility.

Net debt to EBITDA of 0.74 suggests modest leverage relative to many small-cap healthcare peers, limiting balance-sheet strain and preserving capital access.

Cash conversion cycle at zero implies working-capital discipline, which can stabilize liquidity and execution compared with peers that tie up more cash in operations.

Weaknesses

Return on invested capital of -1.36% shows capital is not yet generating economic returns, leaving CRVO structurally behind profitable peers on value creation.

The absence of reported operating and gross margin strength suggests limited evidence of durable unit economics, which weakens competitive positioning versus established peers.

A net debt to EBITDA ratio above zero still matters because negative returns can make even moderate leverage more constraining than it appears versus stronger peers.

Opportunities

If management converts strong liquidity into higher-return deployment, CRVO can narrow the profitability gap versus peers that already monetize capital more efficiently.

The low leverage profile creates room to fund growth initiatives or restructuring without immediate balance-sheet stress, unlike more indebted peers.

Working-capital efficiency can support faster reinvestment cycles, which may improve operating flexibility relative to peers with slower cash conversion.

Threats

Persistent negative ROIC raises the risk that peers with positive returns will compound faster, widening CRVO’s structural gap in capital efficiency.

If liquidity is used to offset weak profitability rather than to improve returns, the company may lag peers that translate balance-sheet strength into earnings growth.

Moderate leverage can become more burdensome if operating performance stays weak, especially versus peers with stronger margins and self-funding capacity.

Overall Score

CRVO’s balance sheet is comparatively resilient, but negative capital returns and limited evidence of durable profitability keep its overall structural positioning below stronger peers.